Nkarta Inc (NKTX)

[jondoeuk]

Additional NKX101 and NKX019 clinical data expected by year-end. The data is expected to include safety and activity data for newly enrolled patients at higher dose monotherapy regimen and extended durability follow-up for previously reported patient responses. Also, in June, the company filed a protocol amendment with the FDA for 019 to optimise the trial's design as they prepare for potential dose expansion cohorts. The amended protocol, now in effect, allows for an increased dose of cyclophosphamide with lymphodepletion, in line with 101, and various expansion cohorts evaluating it in combination with rituximab.